ArticleBMC anesthesiology2026
An evaluation of peripheral nerve damage that may develop following intraneural bupivacaine, dexmedetomidine, and lidocaine injections: multifaceted analysis in an experimental model.
Article in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to investigate the histopathological, electrophysiological, functional, biochemical, and inflammatory changes occurring in peripheral nerves following erroneous intraneural injections of bupivacaine, dexmedetomidine, and lidocaine, and to compare the neurotoxic potentials of these drugs.
methodsThirty-two adult male Sprague-Dawley rats were divided into four groups. The first received intraneural injection of 0.2 ml saline solution to the sciatic nerve. The second received intraneural injection 0.2 ml of 0.5% bupivacaine, the third 20 µg/kg dexmedetomidine diluted to 0.2 ml with normal saline, and the fourth 0.2 ml of 2% lidocaine, all via a 30gauge tuberculin syringe. Sciatic functional index (SFI) and electromyography (EMG) measurements were performed on all groups on days 1, 7, and 14 postoperatively. On the 14th day, the rats were sacrificed by the intraperitoneal administration of high-dose 50 mg/kg sodium thiopental. Following intracardiac blood collection for biochemical analysis, the nerve tissues were removed for histomorphological, immunohistochemical, immunofluorescence examination.
resultsMultimodal analyses revealed that the intraneural injection of bupivacaine, lidocaine, and dexmedetomidine caused varying degrees of nerve damage. Bupivacaine and lidocaine exhibited similar effects in terms of electrophysiological and motor function loss, and bupivacaine caused greater inflammation than lidocaine. Considering the entirety of the electrophysiological, histomorphological, immunohistochemical, and immunofluorescence evaluations, dexmedetomidine emerged as the least neurotoxic and most regenerative anesthetic agent.
conclusionAll intraneural injections can cause varying degrees of nerve damage. Dexmedetomidine showed the least damage compared with bupivacaine and lidocaine within 14 days. Dexmedetomidine may be a safer option as an adjuvant agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.